TrialX API NRG-GI008 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (Circulate-North America).

Study of Chemotherapy Choices Guided by Blood Test Results After Colon Cancer Surgery

Age
99 years or below
Gender
All
Location
1

Brief description of study

Phase II and III: To compare time to DFS event (recurrence, second primary colorectal can cer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

Online study

The purpose of this research study is to learn how different chemotherapy treatment plans compare for people who have had colon cancer removed with surgery and who have a positive blood test for remaining cancer signals (called ctDNA, a blood test that looks for tiny pieces of tumor DNA in the blood). The study will compare how long people stay free of the cancer coming back, developing a new colorectal cancer, or dying.

Participants will receive 1 of 2 chemotherapy treatment plans for about 6 months. Both treatment plans use standard chemotherapy medicines, but the combinations are different. The study will track whether participants have a cancer recurrence, a second new colorectal cancer, or death over time.

Who can participate:
People who have had colon cancer removed with surgery may be able to participate if they:

  • Have a positive ctDNA blood test after surgery

Updated on 20 Mar 2026. Study ID: 89-57152
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator